Stock OPNT OPIANT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Opiant Pharmaceuticals, Inc. Stock

Equities

OPNT

US6837501039

Biotechnology & Medical Research

Chart Opiant Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Opiant Pharmaceuticals, Inc.

Indivior completes acquisition of Opiant Pharmaceuticals AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals MT
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index CI
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index CI
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders. CI
Transcript : Opiant Pharmaceuticals, Inc. - Shareholder/Analyst Call
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals MT
Indivior announces expiry of waiting period for Opiant purchase AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires MT
Indivior Nears Acquisition of Opiant Pharmaceuticals MT
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals RE
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose CI
Insider Sell: Opiant Pharmaceuticals MT
Opiant Pharmaceuticals Completes Rolling Submission of New Drug Application for Potential Opioid Overdose Drug MT
More news

Analyst Recommendations on Opiant Pharmaceuticals, Inc.

Oppenheimer Initiates Coverage on Opiant Pharmaceuticals With Outperform Rating, $42 Price Target MT
More recommendations

Press releases Opiant Pharmaceuticals, Inc.

OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) AQ
OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K) AQ
OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) AQ
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC GL
More press releases

News in other languages on Opiant Pharmaceuticals, Inc.

Bolsa de Madrid: Jerome vuelve en la segunda semana
Jerome revient en deuxième semaine
En Direct des Marchés : BNP Paribas, TotalEnergies, L'Oréal, Scor, Casino, CVS, Bayer, Siemens, BP...
MÄRKTE USA/Leichter - Anleger agieren zurückhaltend
MÄRKTE USA/Uneinheitlich - Anleger sind vorsichtig
More news

Company Profile

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.39% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.61% 96.84B
ARGENX SE Stock argenx SE
-0.70% 21.48B
BIONTECH SE Stock BioNTech SE
-18.14% 20.82B
GENMAB A/S Stock Genmab A/S
-7.22% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.70% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.89% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.12% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.25% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. OPNT Stock